The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
p53 protein accumulation and gene mutations in human glioma cell lines
Abstract
Mutations in, and aberrant expression of, the p53 tumor suppressor gene were assessed in 17 cell lines derived from human malignant brain tumors (glioblastoma multiforme). Ex‐ons 5 through 8 were screened by single strand conformational polymorphism analysis (SSCP), followed by direct DNA sequencing. Mutations were found in 6 of 17 glioma cell lines, i.e., at a frequency similar to that found in primary malignant gliomas. Loss of the wild type allele was observed in 4 of the mutated cell lines. Two cell lines had the same mutation (CGG → TGG; Arg → Trp) in codon 248. Five of 6 mutations were transitions, 4 of which occurred at CpG dinucleotides. In one cell line a 10‐bp deletion at the intron 4/exon 5 junction was found. Five of 6 glioma cell lines contained a mutation identical to that in the respective primary tumor despite prolonged in vitro culture (140‐221 passages). Thus, the acquisition of p53 mutations during culture appears to be infrequent. Two cell lines derived from heterozygous tumors maintained the wild type p53 allele during long term culture. p53 protein levels were assessed by immunofluorescence cytochemistry and immunoprecipitation followed by Western blot analysis and revealed elevated levels of the p53 protein, although to a variable extent, in all cell lines with p53 mutations. A marked p53 protein accumulation was also observed in two cell lines lacking p53 mutations in exons 5 through 8, indicating that a prolonged half life of the gene product is not solely dependent on an aberrant coding sequence. The remaining cell lines had either low levels or no detectable p53 protein; one of the latter contained a gross rearrangement of the p53 gene. Our results suggest that with respect to p53 gene status, glioma cell lines usually resemble the original tumors and may, therefore, be suitable for studying the biological changes associated with p53 mutations in glial tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The absence of detected p53 protein in BT216 can be explained by the fact that deletion mutations resulting in truncated protein do not lead to detectable protein accumulation [23, 24].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [23]
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 2×
“Three mutations were located at the previously identified hot spots, codons 248 and 273 (Hollstein et al., 1991).”
BackgroundLane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · cited 2×
“It has been proposed (Lane, 1992; Vogelstein and Kinzler, 1992) that the function of p53 is to prevent cells with damaged DNA from dividing until the damage is repaired.”
BackgroundGerm Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · cited 1×
“Mutations of the p53 tumor suppressor gene have been identified in a wide variety of human neoplasms (Hollstein et al., 1991), including the Li-Fraumeni syndrome hereditary tumors (Malkin et al., 1990).”
BackgroundOrita, M., Suzuki, Y., Sekiya, T., & Hayashi, K. (1989) · Genomics · doi:10.1016/0888-7543(89)90129-8 · Cited by 3,434 · cited 1×
“PCR-SSCP and direct DNA sequencing PCR-SSCP analysis was essentially performed as described by Orita et al. (1989).”
MethodMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 1×
“The p53 protein can be inactivated by mutation or by forming complexes with oncoproteins of DNA tumor viruses (Linzer and Levine, 1979; Werness ef al., 1990) or with the cellular protein mdm2 (Momand et al., 1992).”
BackgroundMutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
Vogelstein, B. (1992) · Cell · doi:10.1016/0092-8674(92)90421-8 · Cited by 1,862 · cited 4×
“The p53 gene encodes a nuclear 53 kDa phosphoprotein which acts as a transcriptional regulator by forming tetramers which bind to specific DNA sequences and exert a negative regulation of cell proliferation (reviewed by Vogelstein and Kinzler, 1992).”
BackgroundInfluentialLinzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813 · cited 1×
“The p53 protein can be inactivated by mutation or by forming complexes with oncoproteins of DNA tumor viruses (Linzer and Levine, 1979; Werness ef al., 1990) or with the cellular protein mdm2 (Momand et al., 1992).”
BackgroundMolecular basis of base substitution hotspots in Escherichia coli
Coulondre, C., Miller, J. H., Farabaugh, P. J., & Gilbert, W. (1978) · Nature · doi:10.1038/274775a0 · Cited by 1,193 · cited 1×
“The mechanism leading to this base exchange is thought to involve spontaneous hydrolytic deamination of 5-methylcytosine to thymine (Coulondre et aL, 1978), which results in a C -+ T transitiop.”
BackgroundClonal expansion of p53 mutant cells is associated with brain tumour progression
Sidransky, D., Mikkelsen, T., Schwechheimer, K., Rosenblum, M. L., Cavanee, W., & Vogelstein, B. (1992) · Nature · doi:10.1038/355846a0 · Cited by 670
Milner, J., & Medcalf, E. A. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612 · cited 2×
“In the same study (Milner and Medcalf, 1991), another p53 variant mutated at codon 248 was found not to affect the conformation of co-translated wild type p53.”
BackgroundBIGNER, D. D., BIGNER, S. H., PONTÉN, J., WESTERMARK, B., MAHALEY, M. S., RUOSLAHTI, E., HERSCHMAN, H., ENG, L. F., & WIKSTRAND, C. J. (1981) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198105000-00001 · Cited by 480
Harvey, D. M., & Levine, A. J. (1991) · Genes & Development · doi:10.1101/gad.5.12b.2375 · Cited by 453
Bergsagel, D. J., Finegold, M. J., Butel, J. S., Kupsky, W. J., & Garcea, R. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204093261504 · Cited by 415 · cited 1×
“Despite the occasional identification of DNA sequences related to those of BK and SV40 viruses (Dorries et al., 1987; Bergsagel et al., 1992) no evidence has been presented to support a viral etiology in human brain tumours.”
BackgroundCooper, D., & Krawczak, M. (1990) · Human Genetics · doi:10.1007/bf00276326 · Cited by 387
Fults, D., Brockmeyer, D. L., Tullous, M. W., Pedone, C. A., & Cawthon, R. (1992) · PubMed · Cited by 292
Comparative Study of p53 Gene and Protein Alterations in Human Astrocytic Tumors
Louis, D. N., Deimling, A. V., Chung, R. Y., Rubio, M.-P., Whaley, J. M., Eibl, R. H., Ohgaki, H., Wiestler, O. D., Thor, A. D., & Seizinger, B. R. (1993) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199301000-00005 · Cited by 228 · cited 1×
“Louis et al. (1993) have observed that a significant fraction of glioblastomas (29”
BackgroundSelf-citationMutations of the p53 tumor suppressor gene in neoplasms of the human nervous system
Ohgaki, H., Eibl, R. H., Reichel, M. B., Mariani, L., Petersen, I., Höll, T., Wiestler, O. D., Kleihues, P., Schwab, M., & Gehring, M. (1993) · Molecular Carcinogenesis · doi:10.1002/mc.2940080203 · Cited by 226
Self-citationMolecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53.
Harlow, E., Williamson, N. M., Ralston, R., Helfman, D. M., & Adams, T. E. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.7.1601 · Cited by 174 · cited 1×
“The pR4-2p.53 cDNA clone encompassing the entire coding region of the gene (Harlow et al., 1985) was used to probe the 5 cell lines without detectable p53 protein for structural alterations at thep.53 locus by Southern blot hybridization.”
Methodp53 abnormalities in different subtypes of human sarcomas.
Andreassen, Å. K., Øyjord, T., Hovig, E. J., Holm, R., Flørenes, V. A., Nesland, J. M., Myklebost, O., Høie, J., Bruland, Ø. S., & Børresen‐Dale, A. (1993) · PubMed · Cited by 150
Wagata, T., Shibagaki, I., Imamura, M., Shimada, Y., Toguchida, J., Yandell, D. W., Ikenaga, M., Tobe, T., & Ishizaki, K. (1993) · PubMed · Cited by 143
p53 immunostaining as a marker of malignant disease in diagnostic cytopathology
Hall, P. A., Ray, A., Lemoine, N., Midgley, C. A., Krausz, T. N., & Lane, D. P. (1991) · The Lancet · doi:10.1016/0140-6736(91)90586-e · Cited by 132
Bigner, S. H., Bullard, D. E., Pegram, C. N., Wikstrand, C. J., & Bigner, D. D. (1981) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-198107000-00004 · Cited by 122 · cited 1×
“The most remarkable change is the frequently observed loss of glial fibrillary acidic protein expression after several passages in vitro (Bigner et al., 1981).”
BackgroundAssociation of polyomaviruses JC, SV40, and BK with human brain tumors
Dörries, K., Loeber, G., & Meixensberger, J. (1987) · Virology · doi:10.1016/0042-6822(87)90071-7 · Cited by 119
A Correlative Study of p53 Protein Alteration and p53 Gene Mutation in Glioblastoma Multiforme
Newcomb, E. W., Madonia, W. J., Pisharody, S., Lang, F. F., Koslow, M., & Miller, D. C. (1993) · Brain Pathology · doi:10.1111/j.1750-3639.1993.tb00749.x · Cited by 118
Saxena, A., Clark, W. C., Robertson, J. T., Ikejiri, B. L., Oldfield, E. H., & Ali, I. U. (1992) · PubMed · Cited by 94
Kress, S., König, J., Schweizer, J., Löhrke, H., Bauer-Hofmann, R., & Schwarz, M. (1992) · Molecular Carcinogenesis · doi:10.1002/mc.2940060210 · Cited by 92 · cited 1×
“Murine embryo fibroblasts (Harvey and Levine, 1991) and cell lines derived from murine liver tumors (Kress et al., 1992) have been shown to undergo p53 gene mutations during cell culture.”
BackgroundThe p53 tumour suppressor gene and product.
Levine, A. J. (1992) · PubMed · Cited by 68
Identification of RNA splicing errors resulting in human ornithine transcarbamylase deficiency.
Carstens, R. P., Fenton, W. A., & Rosenberg, L. R. (1991) · Europe PMC (PubMed Central) · Cited by 62
Bigner, S. H., Mark, J., & Bigner, D. D. (1987) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(87)90094-x · Cited by 43 · cited 2×
“However, chromosomal markers, if already present in the primary culture, are usually retained (Bigner et al., 1987).”
BackgroundWestphal, M., Hänsel, M., Brunken, M., König, A., Köppen, J. A., & Herrmann, H. D. (2008) · Experimental Cell Biology · doi:10.1159/000163411 · Cited by 25 · cited 1×
“MATERIAL AND METHODS Cell lines, culture conditions and primary tumor samples Cell lines were established between 1985 and 1991 from human glioblastomas, as previously described (Westphal et al., 1987).”
MethodSelf-citationPROTOONCOGENE EXPRESSION IN HUMAN GLIOMA DERIVED CELL-LINES
Hamel, W., Westphal, M., & Shepard, H. M. (1992) · International Journal of Oncology · doi:10.3892/ijo.1.6.673 · Cited by 11 · cited 1×
“Cell lines have been kept in culture continuously (32 to 284 passages) to allow their further characterization (Westphal et ul., 1987; Hamel et al., 1992).”
BackgroundSelf-citation
Cited by
Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A., & Van Meir, E. G. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00536.x · Cited by 569
“Alternatively, mutation of TP53gene could occur in culture, but this is an uncommon event (2,39).”
BackgroundMetellus, P., Coulibaly, B., Colin, C., de Paula, A. M., Vasiljevic, A., Taieb, D., Barlier, A., Boisselier, B., Mokhtari, K., Wang, X. W., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0777-8 · Cited by 289
Gomez‐Manzano, C., Fueyo-Margareto, J., Kyritsis, A. P., Steck, P. A., Roth, J. A., McDonnell, T. J., Steck, K. D., Levin, V. A., & Yung, W. K. A. (1996) · PubMed · Cited by 228
The p53 gene and its role in human brain tumors
Bögler, O., Su Huang, H. ‐., Kleihues, P., & Cavenee, W. K. (1995) · Glia · doi:10.1002/glia.440150311 · Cited by 187
Self-citationExpression of the neural RNA‐binding protein Musashi1 in human gliomas
Toda, M., Iizuka, Y., Yu, W., Imai, T., Ikeda, E., Yoshida, K., Kawase, T., Kawakami, Y., Okano, H., & Uyemura, K. (2001) · Glia · doi:10.1002/glia.1034 · Cited by 162
Metadata
- Authors
- Anker, L., Ohgaki, H., Ludeke, B. I., Herrmann, H., Kleihues, P., & Westphal, M.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- University of Zurich (CH)
- Corresponding author
- Westphal, Manfred
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1993-12-02
- Volume
- 55
- Issue
- 6
- Pages
- 982-987
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2002666984
- Cited by
- 66
- References
- 34
- Citations by year
- 2026: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 1 · 2014: 3 · 2013: 4 · 2012: 1
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- p53, glioma cell lines, glioblastoma, TP53 mutation, p53 accumulation, tumor suppressor, loss of heterozygosity, malignant brain tumors
- MeSH terms
- Base Sequence, Chromosome Deletion, Codon, Exons, Female, Glioma, Humans, Male, Molecular Sequence Data, Precipitin Tests, Tumor Cells, Cultured, Blotting, Western, Polymerase Chain Reaction, Genes, p53, Tumor Suppressor Protein p53, Point Mutation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.